Skip to content

Empowerment-Based Health Education and Type 2 Diabetes Mellitus

The Impact of Empowerment-Based Health Education on Self-Management in Patients With Type 2 Diabetes Mellitus: A Randomized Control Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07524166
Enrollment
50
Registered
2026-04-13
Start date
2025-08-01
Completion date
2025-12-31
Last updated
2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabete Mellitus, Diabetes, Diabetes Mellitus, Type 2

Brief summary

Empowerment-based education may offer a sustainable approach to type 2 diabetes management, yet rigorous evidence within the Chinese healthcare context was lacking.

Interventions

BEHAVIORALEmpowerment-Based Health Education

The program consisted of six weekly sessions, each lasting approximately 60-90 minutes, including 1) introducing introducing the empowerment philosophy; 2) enhancing diabetes knowledge and correct misconceptions through guided questioning and a "Myth Busters" group activity; 3) encouraging participants to reflect on their understanding of the disease; dietary management by teaching the food exchange method through hands-on activities with food models; 5) facilitating discussions on benefits and barriers to physical activity; teaching participants how to calculate appropriate exercise intensity; 6) sharing participants' personal progress and guiding them to develop individualized long-term self-management plans.

Sponsors

Eotvos Lorand University
Lead SponsorOTHER
Jiaxing University
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

1. diagnosed with T2DM according to clinical record; 2. aged 40 years or older; 3. duration of diabetes of at least 6 months; 4. ability to communicate and complete questionnaires independently; 5. provision of written informed consent.

Exclusion criteria

1. presence of severe diabetes complications (e.g., renal failure, proliferative retinopathy, severe neuropathy); 2. diagnosis with other major chronic illnesses (e.g., cancer, severe heart failure); 3. pregnancy or lactation; 4. participation in other interventional studies during the trial period; 5. cognitive or psychiatric disorders that would impede participation.

Design outcomes

Primary

MeasureTime frameDescription
Glycated hemoglobin (HbA1c)From enrollment to the end of treatment at 6 weekslevel of Glycated hemoglobin (HbA1c) , which aimed to reflect average blood glucose levels .
fasting plasma glucose (FPG)From enrollment to the end of treatment at 6 weeksLelel of Glycemic control, which reflects immediate glycemic status

Secondary

MeasureTime frameDescription
Diabetes-specific knowledgeFrom enrollment to the end of treatment at 6 weeksScore of Diabetes Knowledge Test (DKT).
Self-efficacyFrom enrollment to the end of treatment at 6 weeksScore of Diabetes Management Self-Efficacy Scale (DMSES).
diabetes self-management behaviorsFrom enrollment to the end of treatment at 6 weeksScore of Diabetes Self-Care Activities (SDSCA) measure.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 14, 2026